Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
|Articles|February 1, 2008
New Products & Services
Cherry Hill, NJ-Vision USA's sport bifocal safety glasses have soft rubber nose and ear pads and vents between lenses and frame for enhanced comfort.
Advertisement
Bifocal glasses provide safety, magnification, comfort
For more information, visit
For more information, visit
Laser bridges allow precise laser placement
For more information, visit
Book explains female incontinence, Tx to patients
For more information, visit
Advertisement
Related to this article
Perioperative durvalumab (Imfinzi) plus neoadjuvant enfortumab vedotin-ejfv (Padcev) cut the risk of EFS events by 49% and death by 42% in cisplatin-ineligible MIBC.
The PROTEUS substudy addresses a key limitation of the main study, which had no surgery-alone control arm.
At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
The phase 1/2 CELC-G-201 study found preliminary antitumor activity and manageable toxicity with gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer.
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Advertisement
Advertisement
Trending on Urology Times
1
PROTEUS Substudy: Perioperative apalutamide plus ADT improves EFS vs surgery alone
2
VOLGA: Durvalumab plus enfortumab vedotin improves EFS, OS in MIBC
3
Adding perioperative pembrolizumab to chemotherapy does not improve EFS in MIBC
4
KLK2-comPAS trial explores dual T-cell engagement in mCRPC
5